Dermal fillers (필러).

Cross-linked hyaluronic acid — a sugar molecule that occurs naturally in skin — is injected to add volume or reshape contour. Different products are engineered for different tissue depths: thin gels for lips and fine lines, medium gels for cheeks, thick/robust gels for chin and jawline.

Imported: Juvederm (Allergan), Restylane (Galderma), Belotero (Merz), Teosyal (Teoxane). Korean domestic: Neuramis, Revolax, Princess, Mediform. Domestic brands typically cost 30–50% less per syringe with comparable cross-linking technology. All major brands are KFDA-approved.

Brand and line (each brand has multiple products for different depths — get the specific one). Price per cc. Whether hyaluronidase (the dissolving agent) is on-site. Whether the injector is a doctor or a nurse — in Korea, most injectable work is performed by licensed physicians, but clarify.

1–3 days of swelling in most areas; 3–5 days for lips. Occasional bruising depending on site. The "final" result is visible at 2 weeks after initial swelling resolves.

Korean brands: ₩300,000–₩600,000 per cc. Imported brands: ₩500,000–₩1,200,000 per cc. A standard cheek augmentation uses 2–4 cc; a full lip augmentation uses 1 cc; chin projection uses 1–3 cc.

"If I'm not happy with the result in 2 weeks, what's your dissolution policy and how soon can I come in?" A reversible product has no excuse for a clinic that won't dissolve on request.

A typical Korean filler (필러) appointment opens with a quiet consultation, a set of standardised photographs, and a marking pencil. The injector sits the patient up and traces the planned injection points along the cheek, tear trough, chin, jawline, lip border, or nasal dorsum, depending on the plan. Topical numbing cream is then applied to the entire treatment area for 25 to 30 minutes under cling film. Most modern hyaluronic acid (히알루론산) products also contain lidocaine premixed into the gel, so the discomfort drops sharply within the first second of injection as the anaesthetic diffuses ahead of the product.

Two delivery techniques are common in Korea. A 27 to 30 gauge sharp needle is used for precise, small-volume placements such as lip border (입술 필러) and lateral chin (턱끝 필러). A blunt-tip cannula, introduced through a single 22 to 25 gauge entry port, is used for tear trough (눈밑 필러), cheek (광대 필러), and jawline work, because the blunt tip pushes vessels aside rather than puncturing them and produces less bruising over a longer treatment area. The sensation across both techniques is brief sharp pressure at each point, followed by a fullness or stretch as the gel diffuses into the tissue plane. Most appointments take 30 to 45 minutes including numbing.

What patients underestimate is the timeline of how the result settles. Day 0 leaves the clinic with an immediate visible volume change and, in most areas, some swelling on top of it. Day 1 to 3 is peak swelling, often with asymmetric puffiness that can look uneven; lips swell most, tear troughs swell unpredictably. Day 7 brings the bulk of the swelling resolution and the first honest preview of the result. The product itself continues to integrate, hydrate, and equilibrate with surrounding tissue over weeks 2 to 4, which is when reputable Korean clinics schedule the touch-up review. Judging the result before the 2-week mark is a common patient error.

Hyaluronic acid fillers have one of the largest published safety datasets in aesthetic medicine, but the dataset includes both reassuring volume numbers and a small number of serious complications that every patient should understand before consenting. None of the following replaces a clinic-specific consultation, and none of it is medical advice.

The most-cited serious complication is intravascular injection leading to vascular occlusion. A literature review and meta-analysis of vascular complications after facial filler injection (PMID: 31360292) catalogued the published cases worldwide and identified the glabella, nose, and nasolabial fold as the highest-risk anatomical zones, with skin necrosis and, rarely, ophthalmic-artery embolism leading to vision loss as the most severe outcomes. Published large series place the per-syringe vascular event rate in the range of approximately 1 in 5,000 to 1 in 15,000, depending on operator volume and area treated. The DeLorenzi pulsed high-dose hyaluronidase protocol (PMID: 28333326) is now the reference emergency response: legitimate Korean and international clinics keep hyaluronidase on-site at all times, and a clinic that cannot show you a stocked emergency kit and a written vascular-event protocol is not a clinic to choose. Ask before you book.

On product-specific safety, a multicenter prospective observational study of YVOIRE (LG Chem) for nasolabial folds (PMID: 35357748) reported low rates of delayed adverse reactions across two cohorts and confirmed full clinical biodegradation in the majority of patients within 12 months. A Phase III randomised controlled trial of Neuramis Deep Lidocaine versus Restylane (PMID: 26910660) reached non-inferiority on Wrinkle Severity Rating Scale outcomes at standard nasolabial dosing in 58 patients, with comparable adverse-event profiles. A larger 48-week trial of Neuramis Volume Lidocaine versus Juvederm Voluma in 88 Korean subjects (PMID: 33476068) reported responder rates above 80% in both arms with similar safety signals. Delayed-onset nodules, biofilm-related late inflammation, and granuloma formation are uncommon but documented for every HA product on the market and present weeks to over a year after injection. Tyndall effect — a bluish discoloration visible under thin skin, most often in the tear trough — is reported at approximately 0.9% in pooled tear-trough filler data (PMID: 37684413) and is reversible with hyaluronidase.

Filler is contraindicated in pregnancy and breastfeeding by every major manufacturer label, and reputable Korean clinics will postpone treatment until after weaning. Active skin infection at the injection site, uncontrolled autoimmune conditions, and recent dental work are standard relative contraindications worth raising in your consultation.

Hyaluronic acid filler is a volumiser. It physically occupies space in the dermis or in the deeper fat compartments to add structural support, soften a contour, or replace lost volume. Korean clinics typically use it for the tear trough (눈밑 필러) to soften the hollow between the lower lid and cheek, the cheek and zygomatic arch (광대 필러) for mid-face support, the chin (턱끝 필러) for projection and balance, the jawline for definition, the lips (입술 필러) for border and body, the nasolabial folds and marionette lines for static crease softening, and the nasal dorsum and tip (콧대 필러) for non-surgical rhinoplasty. The same single material is engineered into different cross-link densities and particle sizes for different tissue depths — thin gels for lips and fine lines, mid-density gels for tear troughs and lateral cheeks, robust gels for chin and jaw structural work.

What filler does not do is equally important. It does not lift sagging skin; that work belongs to PDO threads, HIFU, Ultherapy, or surgery. It does not soften muscle-driven dynamic wrinkles such as forehead lines, glabellar 11s, or crow's feet — those are botulinum toxin territory. It does not change skin texture, pore size, or pigmentation, all of which are addressed by lasers, skin boosters, or topical regimens. It cannot fix asymmetry caused by underlying bone structure or by chronic muscle imbalance. Korean injectors will often decline a filler request if the actual driver of what the patient sees is one of these other layers, and will recommend a combination plan instead.

Korean injection style has shifted toward layered, drop-by-drop placement with multiple smaller-syringe touch-ups rather than a single large bolus. Patients in their mid-twenties to early thirties typically receive small volumes for lip definition, tear trough softening, and light chin or jawline contouring. Patients over 35 more often combine filler with biostimulators or skin boosters because the contributors to age-related facial change are layered rather than purely volumetric. Discuss with your provider which layer is driving what you see in the mirror.

Published longevity and outcome data for hyaluronic acid filler are extensive, area-specific, and increasingly objective thanks to imaging studies. The classic clinical reference point is roughly 6 to 12 months for lips, 9 to 18 months for tear troughs, and 12 to 24 months for cheek and chin work, with substantial variation by product, cross-link density, and individual metabolism. A clinical review of HA filler science and uses (PMID: 27363762) summarises the historical 4 to 6 month duration estimate and notes that newer cross-linking technologies extend that window meaningfully. A meta-analysis of HA for lip augmentation found significant improvement maintained at 6 months but a noticeable decay by 12 months, with roughly half of patients still showing benefit at the one-year mark.

Imaging studies have changed how the field thinks about persistence. A long-term magnetic resonance imaging study of HA filler localisation (PMID: 33002985) demonstrated that cross-linked HA is detectable in the lateral cheek and zygomatic area for at least 27 months in the superficial fat compartment, while more mobile areas such as the chin show near-complete degradation by 19 months. A 2024 review of 33 MRI studies in the mid-face (PMID: 39015357) reported that filler signal can persist between 2 and 15 years across products, with confidence intervals centred well beyond the duration patients are typically quoted at consultation. The clinical implication is not that fillers stop working earlier than they degrade, but that residual product can accumulate over repeat treatments — which is part of why Korean injectors have moved toward smaller, more frequent top-ups rather than larger annual sessions.

Patient-reported outcomes are now standardised on the FACE-Q aesthetic module. A study of HA filler for non-surgical rhinoplasty using the FACE-Q scale (PMID: 35398952) reported significant improvement in patient-reported self-esteem and aesthetic satisfaction across all subscales after small-particle HA injection into the nasal soft tissues. Comparative trials of Korean domestic products against Western reference fillers — Neuramis Deep versus Restylane (PMID: 26910660), Neuramis Volume versus Juvederm Voluma (PMID: 33476068) — consistently show non-inferiority on responder rates and similar safety signals at matched dosing, which underpins Korean clinics' willingness to use domestic brands at lower price points. Polydeoxyribonucleotide (PDRN) injectables, increasingly paired with filler in Korean protocols for post-procedure skin recovery, have shown signal in dermal regeneration studies, though the specific filler-plus-PDRN combination still lacks rigorous head-to-head trial data. Ask your injector to walk through their product selection logic and evidence base.

Korean filler (한국 필러) practice in 2026 is defined by smaller syringes, more frequent reviews, and a clear preference for natural micro-volume over the more obvious filler aesthetic associated with some Western markets. Inbound search traffic to Gangnam clinics for terms such as korean filler, lip filler korea, tear trough filler korean, Yvoire filler, and Neuramis filler reflects that international visibility, with the domestic brand catalogue — Yvoire (LG Chem), Neuramis (Medytox), Revolax, Princess, Mediform — sitting alongside imported Juvederm, Restylane, Belotero, and Teosyal at most mid-tier and premium clinics.

Technique has shifted toward layered drop-by-drop placement: 0.05 to 0.1 mL micro-aliquots delivered through cannula across a treatment area, rather than a single 1 mL bolus. The stated rationale is more even diffusion, reduced bruising, and easier titration over multiple visits. Filler dissolver — hyaluronidase (히알루로니다아제) — is stocked routinely; patients can ask to dissolve a result they are unhappy with at a follow-up visit, separate from emergency vascular use. Biostimulator alternatives (Sculptra polylactic acid, Radiesse calcium hydroxylapatite, polynucleotide products) are increasingly offered alongside HA for patients seeking longer duration or collagen remodelling rather than passive volume.

Around the procedure, recovery and skin-quality add-ons have multiplied. PDRN injectables (Rejuran and equivalents) are commonly paired with filler for post-treatment skin recovery and scar-quality improvement. The glass skin (유리피부) endpoint frames the aesthetic target: clear, light-reflecting skin with subtle structural support rather than visible filler shapes. Exosome facials (엑소좀) are increasingly offered as post-procedure adjuncts; the published evidence for cosmetic exosome use remains early, and patients should ask whether the clinic uses regulated, traceable products. The consistent Korean message across all of these trends is the same: less product, more often, with adjustment built into the plan rather than committed up front.

Is it safe during pregnancy or breastfeeding? No — manufacturer labels and reputable Korean clinics decline cosmetic filler during pregnancy and breastfeeding. Treatment is postponed until after weaning. Ask your provider for their written policy.

Can I see the result immediately? Partly. The volume change is visible as you sit up from the chair, but it is overlaid with day-0 swelling. The honest preview comes at day 7, and the settled result at week 2 to 4. Reputable clinics schedule the review at 2 weeks rather than judging results on the same day.

How long until it settles? Most areas settle by week 2 to 4. Lips can take 2 to 3 weeks for swelling to fully resolve; tear troughs can take longer because the periorbital tissue retains fluid unpredictably. Avoid major events for at least 2 weeks after treatment.

Can I dissolve it if I do not like it? Yes — hyaluronic acid filler is reversible with hyaluronidase, which most Korean clinics stock on-site. Ask in advance about the clinic's dissolution policy and fee structure. A reversible product has no excuse for a clinic that refuses to dissolve on request.

What is the rare risk I should know about? Vascular occlusion. Intravascular injection or external compression of an artery by filler can cause skin necrosis or, very rarely, vision loss. Published rates are low — on the order of 1 in 5,000 to 15,000 syringes (PMID: 31360292) — but the consequence is severe, which is why hyaluronidase availability and a written emergency protocol are non-negotiable when choosing a clinic.

Can I fly after filler? Most Korean injectors advise waiting 24 to 48 hours before flying, primarily for swelling management rather than safety. Long-haul flights amplify periorbital and lip swelling; plan accordingly.

Should I avoid dental work near filler? Major dental procedures within 2 weeks before or after filler are commonly discouraged, because oral manipulation and transient bacteraemia have been associated with delayed inflammatory nodules in published case series. Ask your provider for their specific window.

Will it migrate over time? Migration is documented, particularly with lip filler placed superficially or with repeat overfilling above the vermilion border. MRI studies (PMID: 33002985, PMID: 39015357) show that product tends to stay where it is placed in the mid-face but can spread along tissue planes over years in mobile areas. Conservative dosing reduces the risk.

Are Korean brands as good as Restylane or Juvederm? Published non-inferiority data for Neuramis versus Restylane (PMID: 26910660) and Neuramis Volume versus Juvederm Voluma (PMID: 33476068) support comparable performance at matched dosing for nasolabial and mid-face indications, with similar safety profiles. Brand choice in Korean clinics is often driven by price, rheology preference, and clinician familiarity rather than efficacy gap.

Can I combine with botox or skin boosters in one visit? Yes — combining filler with botulinum toxin and a skin booster such as Rejuran or Profhilo in a single visit is a common Korean protocol. Sequencing matters: most injectors will perform filler first, then botulinum toxin, then any skin booster. Discuss the combination with your provider, and expect slightly longer combined downtime than for any single product.